JP2022513350A5 - - Google Patents
Info
- Publication number
- JP2022513350A5 JP2022513350A5 JP2021545279A JP2021545279A JP2022513350A5 JP 2022513350 A5 JP2022513350 A5 JP 2022513350A5 JP 2021545279 A JP2021545279 A JP 2021545279A JP 2021545279 A JP2021545279 A JP 2021545279A JP 2022513350 A5 JP2022513350 A5 JP 2022513350A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024030048A JP2024059913A (ja) | 2018-10-15 | 2024-02-29 | がんの併用療法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862745464P | 2018-10-15 | 2018-10-15 | |
| US62/745,464 | 2018-10-15 | ||
| US201962802091P | 2019-02-06 | 2019-02-06 | |
| US62/802,091 | 2019-02-06 | ||
| US201962854494P | 2019-05-30 | 2019-05-30 | |
| US62/854,494 | 2019-05-30 | ||
| PCT/US2019/056210 WO2020081497A1 (en) | 2018-10-15 | 2019-10-15 | Combination therapy for cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024030048A Division JP2024059913A (ja) | 2018-10-15 | 2024-02-29 | がんの併用療法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022513350A JP2022513350A (ja) | 2022-02-07 |
| JP2022513350A5 true JP2022513350A5 (https=) | 2022-10-20 |
| JPWO2020081497A5 JPWO2020081497A5 (https=) | 2022-10-20 |
| JP7448552B2 JP7448552B2 (ja) | 2024-03-12 |
Family
ID=68393113
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021545279A Active JP7448552B2 (ja) | 2018-10-15 | 2019-10-15 | がんの併用療法 |
| JP2024030048A Pending JP2024059913A (ja) | 2018-10-15 | 2024-02-29 | がんの併用療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024030048A Pending JP2024059913A (ja) | 2018-10-15 | 2024-02-29 | がんの併用療法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210332137A1 (https=) |
| EP (1) | EP3867274A1 (https=) |
| JP (2) | JP7448552B2 (https=) |
| KR (1) | KR20210076025A (https=) |
| CN (1) | CN113166242B (https=) |
| AU (1) | AU2019361923A1 (https=) |
| BR (1) | BR112021007134A2 (https=) |
| CA (1) | CA3114955A1 (https=) |
| IL (1) | IL282093A (https=) |
| MA (1) | MA53911A (https=) |
| MX (1) | MX2021004226A (https=) |
| SG (1) | SG11202103153VA (https=) |
| TW (1) | TWI835885B (https=) |
| WO (1) | WO2020081497A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3672990A1 (en) | 2017-08-25 | 2020-07-01 | Five Prime Therapeutics, Inc. | B7-h4 antibodies and methods of use thereof |
| JP2021514379A (ja) | 2018-02-21 | 2021-06-10 | ファイブ プライム セラピューティクス， インコーポレイテッド | Ｂ７−ｈ４抗体製剤 |
| MA52416A (fr) | 2018-03-02 | 2021-04-21 | Five Prime Therapeutics Inc | Anticorps b7-h4 et leurs procédés d'utilisation |
| IL310780A (en) * | 2020-08-18 | 2024-04-01 | Abl Bio Inc | Anti-b7-h4/anti-4-1bb bispecific antibodies and use thereof |
| JP2024501894A (ja) | 2021-01-04 | 2024-01-16 | メルサナ セラピューティクス インコーポレイテッド | Ｂ７ｈ４ターゲティング抗体－薬物コンジュゲートおよびその使用方法 |
| GB202402046D0 (en) * | 2024-02-14 | 2024-03-27 | Bivictrix Ltd | Therapeutic antibodies |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US6174666B1 (en) | 1992-03-27 | 2001-01-16 | The United States Of America As Represented By The Department Of Health And Human Services | Method of eliminating inhibitory/instability regions from mRNA |
| ES2434961T5 (es) | 1998-04-20 | 2018-01-18 | Roche Glycart Ag | Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo |
| EP1176195B1 (en) | 1999-04-09 | 2013-05-22 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| CA2388245C (en) | 1999-10-19 | 2012-01-10 | Kyowa Kirin Co., Ltd. | The use of serum-free adapted rat cells for producing heterologous polypeptides |
| EP2322644A1 (en) | 2000-06-28 | 2011-05-18 | GlycoFi, Inc. | Methods for producing modified glycoproteins |
| CA2424977C (en) | 2000-10-06 | 2008-03-18 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| ES2639222T5 (es) | 2000-10-06 | 2023-11-24 | Kyowa Kirin Co Ltd | Células que producen unas composiciones de anticuerpo |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| EP2180044A1 (en) | 2001-08-03 | 2010-04-28 | GlycArt Biotechnology AG | Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity |
| CA2478297C (en) | 2002-03-19 | 2013-05-14 | Plant Research International B.V. | Optimizing glycan processing in plants |
| US20040014194A1 (en) | 2002-03-27 | 2004-01-22 | Schering Corporation | Beta-secretase crystals and methods for preparing and using the same |
| CN103540600B (zh) | 2003-01-22 | 2017-12-01 | 罗氏格黎卡特股份公司 | 融合构建体及其用来生产Fc受体结合亲和性和效应子功能提高的抗体的用途 |
| JP2008539753A (ja) | 2005-05-09 | 2008-11-20 | グリクアート バイオテクノロジー アクチェンゲゼルシャフト | 修飾ｆｃ領域およびｆｃ受容体との結合変更を有する抗原結合分子 |
| BRPI0707290A2 (pt) | 2006-01-17 | 2011-08-16 | Biolex Therapeutics Inc | composições e métodos para humanização e otimização de n-glicanas em plantas |
| US7846724B2 (en) | 2006-04-11 | 2010-12-07 | Hoffmann-La Roche Inc. | Method for selecting CHO cell for production of glycosylated antibodies |
| HRP20131167T1 (hr) * | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| EA201000910A1 (ru) * | 2007-11-30 | 2011-04-29 | Бристоль-Мейерз Сквибб Компани | Конъюгат "моноклональное антитело против в7н4/лекарственное средство" и способы его применения |
| SG10201602394QA (en) | 2011-03-29 | 2016-05-30 | Roche Glycart Ag | Antibody FC Variants |
| US9562099B2 (en) * | 2013-03-14 | 2017-02-07 | Genentech, Inc. | Anti-B7-H4 antibodies and immunoconjugates |
| PH12021552742A1 (en) | 2013-08-01 | 2022-05-23 | Five Prime Therapeutics Inc | Afucosylated anti-fgfr2iiib antibodies |
| JP6943760B2 (ja) * | 2014-09-12 | 2021-10-06 | ジェネンテック， インコーポレイテッド | 抗ｂ７−ｈ４抗体及び免疫複合体 |
| WO2016070001A1 (en) * | 2014-10-31 | 2016-05-06 | Jounce Therapeutics, Inc. | Methods of treating conditions with antibodies that bind b7-h4 |
| NZ733854A (en) * | 2015-02-26 | 2022-07-01 | Merck Patent Gmbh | Pd-1 / pd-l1 inhibitors for the treatment of cancer |
| WO2017106656A1 (en) * | 2015-12-17 | 2017-06-22 | Novartis Ag | Antibody molecules to pd-1 and uses thereof |
| WO2018106862A1 (en) * | 2016-12-07 | 2018-06-14 | Agenus Inc. | Anti-ctla-4 antibodies and methods of use thereof |
| JP7106538B2 (ja) * | 2016-12-07 | 2022-07-26 | アジェナス インコーポレイテッド | 抗体およびその使用方法 |
| EP3672990A1 (en) * | 2017-08-25 | 2020-07-01 | Five Prime Therapeutics, Inc. | B7-h4 antibodies and methods of use thereof |
| EP3755719A1 (en) * | 2018-02-21 | 2020-12-30 | Five Prime Therapeutics, Inc. | B7-h4 antibody dosing regimens |
-
2019
- 2019-10-15 WO PCT/US2019/056210 patent/WO2020081497A1/en not_active Ceased
- 2019-10-15 EP EP19795757.4A patent/EP3867274A1/en active Pending
- 2019-10-15 TW TW108137035A patent/TWI835885B/zh active
- 2019-10-15 SG SG11202103153VA patent/SG11202103153VA/en unknown
- 2019-10-15 KR KR1020217012944A patent/KR20210076025A/ko active Pending
- 2019-10-15 MX MX2021004226A patent/MX2021004226A/es unknown
- 2019-10-15 MA MA053911A patent/MA53911A/fr unknown
- 2019-10-15 CA CA3114955A patent/CA3114955A1/en active Pending
- 2019-10-15 CN CN201980071763.6A patent/CN113166242B/zh active Active
- 2019-10-15 AU AU2019361923A patent/AU2019361923A1/en active Pending
- 2019-10-15 BR BR112021007134-2A patent/BR112021007134A2/pt unknown
- 2019-10-15 JP JP2021545279A patent/JP7448552B2/ja active Active
-
2021
- 2021-04-06 IL IL282093A patent/IL282093A/en unknown
- 2021-04-07 US US17/224,865 patent/US20210332137A1/en active Pending
-
2024
- 2024-02-29 JP JP2024030048A patent/JP2024059913A/ja active Pending